retatrutide triple agonist gip glp-1 glucagon phase 2 obesity trial From to Metabolic Health: Why Is a Game-Changer Triple Agonism Based Therapies for

This observation led to a study where GLP-1 was given to obese patients with T2DM and showed improved glycemic control with no side effects, establishing a proof-of-concept for GLP-1 agonists, which over time led to their use in the treatment of T2DM patients [21]

Honest answer currently expensive

The peptide cost calculator can help you compare costs across different formulations and providers

Am J Physiol Renal Physiol

Wild RA, Rizzo M, Clifton S, et al

People might have one drink to start the evening off: but they wont be tempted into a second or third drink after that (Morgan Stanleys research suggests 50% fewer less drinks per occasion)